Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

STAT Family Protein Expression and Phosphorylation State during moDC Development Is Altered by Platinum-Based Chemotherapeutics.

de Haas N, de Koning C, di Blasio S, Flórez-Grau G, de Vries IJM, Hato SV.

J Immunol Res. 2019 Jun 11;2019:7458238. doi: 10.1155/2019/7458238. eCollection 2019.

2.

Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression-Free and Overall Survival Benchmarks: an International Rare Cancers Initiative (IRCI) Ocular Melanoma study.

Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, Keilholz U, Zimmer L, Patel SP, Piperno-Neumann S, Piulats J, Kivelä TT, Pfoehler C, Bhatia S, Huppert P, Van Iersel LBJ, De Vries IJM, Penel N, Vogl T, Cheng T, Fiorentini G, Mouriaux F, Tarhini A, Patel PM, Carvajal R, Joshua AM.

Ann Oncol. 2019 May 31. pii: mdz176. doi: 10.1093/annonc/mdz176. [Epub ahead of print]

PMID:
31150059
3.

Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity.

Fennemann FL, de Vries IJM, Figdor CG, Verdoes M.

Front Immunol. 2019 Apr 16;10:824. doi: 10.3389/fimmu.2019.00824. eCollection 2019.

4.

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.

Bol KF, Schreibelt G, Rabold K, Wculek SK, Schwarze JK, Dzionek A, Teijeira A, Kandalaft LE, Romero P, Coukos G, Neyns B, Sancho D, Melero I, de Vries IJM.

J Immunother Cancer. 2019 Apr 18;7(1):109. doi: 10.1186/s40425-019-0580-6. Review.

5.

Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy.

Bloemendal M, van Willigen WW, Bol KF, Boers-Sonderen MJ, Bonenkamp JJ, Werner JEM, Aarntzen EHJG, Koornstra RHT, de Groot JWB, de Vries IJM, van der Hoeven JJM, Gerritsen WR, de Wilt JHW.

Ann Surg Oncol. 2019 Mar 4. doi: 10.1245/s10434-019-07274-2. [Epub ahead of print]

PMID:
30830540
6.

Survival of Ovarian Cancer Patients Is Independent of the Presence of DC and T Cell Subsets in Ascites.

Wefers C, Duiveman-de Boer T, Yigit R, Zusterzeel PLM, van Altena AM, Massuger LFAG, De Vries IJM.

Front Immunol. 2019 Jan 11;9:3156. doi: 10.3389/fimmu.2018.03156. eCollection 2018.

7.

Spontaneous Regression of Ovarian Carcinoma After Septic Peritonitis; A Unique Case Report.

Roelofsen T, Wefers C, Gorris MAJ, Textor JC, Massuger LFAG, de Vries IJM, van Altena AM.

Front Oncol. 2018 Nov 29;8:562. doi: 10.3389/fonc.2018.00562. eCollection 2018.

8.

PTEN Hamartoma Tumor Syndrome and Immune Dysregulation.

Eissing M, Ripken L, Schreibelt G, Westdorp H, Ligtenberg M, Netea-Maier R, Netea MG, de Vries IJM, Hoogerbrugge N.

Transl Oncol. 2019 Feb;12(2):361-367. doi: 10.1016/j.tranon.2018.11.003. Epub 2018 Nov 30. Review.

9.

Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy.

Bloemendal M, Rietveld MJA, van Willigen WW, Gerritsen WR, Figdor CG, Bonenkamp JJ, Westdorp H, Boudewijns S, Koornstra RHT, Adang EMM, Schreibelt G, Ottevanger PB, de Vries IJM, Bol KF.

Clin Transl Oncol. 2019 Jun;21(6):774-780. doi: 10.1007/s12094-018-1987-0. Epub 2018 Nov 21.

PMID:
30465182
10.

Human Dendritic Cell Subsets Undergo Distinct Metabolic Reprogramming for Immune Response.

Basit F, Mathan T, Sancho D, de Vries IJM.

Front Immunol. 2018 Nov 1;9:2489. doi: 10.3389/fimmu.2018.02489. eCollection 2018.

11.

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time.

van Willigen WW, Bloemendal M, Gerritsen WR, Schreibelt G, de Vries IJM, Bol KF.

Front Immunol. 2018 Oct 1;9:2265. doi: 10.3389/fimmu.2018.02265. eCollection 2018. Review.

12.

BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?

van Ee TJ, Van Acker HH, van Oorschot TG, Van Tendeloo VF, Smits EL, Bakdash G, Schreibelt G, de Vries IJM.

Vaccines (Basel). 2018 Sep 19;6(3). pii: E65. doi: 10.3390/vaccines6030065. Review.

13.

Interferon Gamma-Induced Protein (IP-10) as Potential Biomarker for Cancer-Related-Fatigue: Results from a 6-month Randomized Controlled Trial.

Ter Veer E, Prinsen H, Sprangers MAG, Zwinderman KAH, Bleijenberg G, van der Pouw Kraan TCTM, de Vries IJM, Wierenga EA, van Laarhoven HWM.

Cancer Invest. 2018;36(7):371-377. doi: 10.1080/07357907.2018.1499933. Epub 2018 Sep 6.

PMID:
30188739
14.

Single-cell analysis reveals that stochasticity and paracrine signaling control interferon-alpha production by plasmacytoid dendritic cells.

Wimmers F, Subedi N, van Buuringen N, Heister D, Vivié J, Beeren-Reinieren I, Woestenenk R, Dolstra H, Piruska A, Jacobs JFM, van Oudenaarden A, Figdor CG, Huck WTS, de Vries IJM, Tel J.

Nat Commun. 2018 Aug 20;9(1):3317. doi: 10.1038/s41467-018-05784-3.

15.

The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies.

Fruhwirth GO, Kneilling M, de Vries IJM, Weigelin B, Srinivas M, Aarntzen EHJG.

Mol Imaging Biol. 2018 Oct;20(5):696-704. doi: 10.1007/s11307-018-1254-3. Review.

16.

Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells.

Sköld AE, Mathan TSM, van Beek JJP, Flórez-Grau G, van den Beukel MD, Sittig SP, Wimmers F, Bakdash G, Schreibelt G, de Vries IJM.

Cancer Immunol Immunother. 2018 Sep;67(9):1425-1436. doi: 10.1007/s00262-018-2204-2. Epub 2018 Jul 13.

17.

Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG.

Wefers C, Schreibelt G, Massuger LFAG, de Vries IJM, Torensma R.

Front Immunol. 2018 Jun 19;9:1412. doi: 10.3389/fimmu.2018.01412. eCollection 2018.

18.

Clinically-Applicable Perfluorocarbon-Loaded Nanoparticles For In vivo Photoacoustic, 19F Magnetic Resonance And Fluorescent Imaging.

Swider E, Daoudi K, Staal AHJ, Koshkina O, van Riessen NK, van Dinther E, de Vries IJM, de Korte CL, Srinivas M.

Nanotheranostics. 2018 Jun 1;2(3):258-268. doi: 10.7150/ntno.26208. eCollection 2018.

19.

Customizing poly(lactic-co-glycolic acid) particles for biomedical applications.

Swider E, Koshkina O, Tel J, Cruz LJ, de Vries IJM, Srinivas M.

Acta Biomater. 2018 Jun;73:38-51. doi: 10.1016/j.actbio.2018.04.006. Epub 2018 Apr 11. Review.

20.

Different Lipid Regulation in Ovarian Cancer: Inhibition of the Immune System.

Wefers C, Duiveman-de Boer T, Zusterzeel PLM, Massuger LFAG, Fuchs D, Torensma R, Wheelock CE, de Vries IJM.

Int J Mol Sci. 2018 Jan 17;19(1). pii: E273. doi: 10.3390/ijms19010273.

21.

Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.

Gorris MAJ, Halilovic A, Rabold K, van Duffelen A, Wickramasinghe IN, Verweij D, Wortel IMN, Textor JC, de Vries IJM, Figdor CG.

J Immunol. 2018 Jan 1;200(1):347-354. doi: 10.4049/jimmunol.1701262. Epub 2017 Nov 15.

22.

Migrating into the Tumor: a Roadmap for T Cells.

van der Woude LL, Gorris MAJ, Halilovic A, Figdor CG, de Vries IJM.

Trends Cancer. 2017 Nov;3(11):797-808. doi: 10.1016/j.trecan.2017.09.006. Epub 2017 Nov 6. Review.

PMID:
29120755
23.

Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein.

Buschow SI, Ramazzotti M, Reinieren-Beeren IMJ, Heinzerling LM, Westdorp H, Stefanini I, Beltrame L, Hato SV, Ellebaek E, Gross S, Nguyen VA, Weinlich G, Ragoussis J, Baban D, Schuler-Thurner B, Svane IM, Romani N, Austyn JM, De Vries IJM, Schuler G, Cavalieri D, Figdor CG.

Oncotarget. 2017 Jun 27;8(40):67439-67456. doi: 10.18632/oncotarget.18698. eCollection 2017 Sep 15.

24.

Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity.

Hato SV, Figdor CG, Takahashi S, Pen AE, Halilovic A, Bol KF, Vasaturo A, Inoue Y, de Haas N, Verweij D, Van Herpen CML, Kaanders JH, van Krieken JHJM, Van Laarhoven HWM, Hooijer GKJ, Punt CJA, Asai A, de Vries IJM, Lesterhuis WJ.

Oncotarget. 2017 May 7;8(33):54434-54443. doi: 10.18632/oncotarget.17661. eCollection 2017 Aug 15.

25.

Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome.

Westdorp H, Kolders S, Hoogerbrugge N, de Vries IJM, Jongmans MCJ, Schreibelt G.

Cancer Lett. 2017 Sep 10;403:159-164. doi: 10.1016/j.canlet.2017.06.018. Epub 2017 Jun 20. Review.

26.

Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients.

Wimmers F, de Haas N, Scholzen A, Schreibelt G, Simonetti E, Eleveld MJ, Brouwers HM, Beldhuis-Valkis M, Joosten I, de Jonge MI, Gerritsen WR, de Vries IJ, Diavatopoulos DA, Jacobs JF.

Sci Rep. 2017 Mar 7;7:43486. doi: 10.1038/srep43486.

27.

Harnessing RNA sequencing for global, unbiased evaluation of two new adjuvants for dendritic-cell immunotherapy.

Mathan TSM, Textor J, Sköld AE, Reinieren-Beeren I, van Oorschot T, Brüning M, Figdor CG, Buschow SI, Bakdash G, de Vries IJM.

Oncotarget. 2017 Mar 21;8(12):19879-19893. doi: 10.18632/oncotarget.15190.

28.

Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity.

van Beek JJ, Gorris MA, Sköld AE, Hatipoglu I, Van Acker HH, Smits EL, de Vries IJ, Bakdash G.

Oncoimmunology. 2016 Sep 2;5(10):e1227902. eCollection 2016.

29.

Proteomics of Human Dendritic Cell Subsets Reveals Subset-Specific Surface Markers and Differential Inflammasome Function.

Worah K, Mathan TSM, Vu Manh TP, Keerthikumar S, Schreibelt G, Tel J, Duiveman-de Boer T, Sköld AE, van Spriel AB, de Vries IJM, Huynen MA, Wessels HJ, Gloerich J, Dalod M, Lasonder E, Figdor CG, Buschow SI.

Cell Rep. 2016 Sep 13;16(11):2953-2966. doi: 10.1016/j.celrep.2016.08.023.

30.

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination.

Boudewijns S, Koornstra RH, Westdorp H, Schreibelt G, van den Eertwegh AJ, Geukes Foppen MH, Haanen JB, de Vries IJ, Figdor CG, Bol KF, Gerritsen WR.

Oncoimmunology. 2016 Jun 17;5(8):e1201625. doi: 10.1080/2162402X.2016.1201625. eCollection 2016 Aug.

31.

Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death.

Di Blasio S, Wortel IM, van Bladel DA, de Vries LE, Duiveman-de Boer T, Worah K, de Haas N, Buschow SI, de Vries IJ, Figdor CG, Hato SV.

Oncoimmunology. 2016 Aug 3;5(8):e1192739. doi: 10.1080/2162402X.2016.1192739. eCollection 2016 Aug.

32.

Improving cancer immunotherapy by targeting the STATe of MDSCs.

de Haas N, de Koning C, Spilgies L, de Vries IJ, Hato SV.

Oncoimmunology. 2016 Jun 27;5(7):e1196312. doi: 10.1080/2162402X.2016.1196312. eCollection 2016 Jul. Review.

33.

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.

Boudewijns S, Bol KF, Schreibelt G, Westdorp H, Textor JC, van Rossum MM, Scharenborg NM, de Boer AJ, van de Rakt MW, Pots JM, van Oorschot TG, Duiveman-de Boer T, Olde Nordkamp MA, van Meeteren WS, van der Graaf WT, Bonenkamp JJ, de Wilt JH, Aarntzen EH, Punt CJ, Gerritsen WR, Figdor CG, de Vries IJ.

Oncoimmunology. 2016 May 31;5(7):e1191732. doi: 10.1080/2162402X.2016.1191732. eCollection 2016 Jul.

34.

Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma.

Vasaturo A, Di Blasio S, Verweij D, Blokx WA, van Krieken JH, de Vries IJ, Figdor CG.

Histopathology. 2017 Mar;70(4):643-649. doi: 10.1111/his.13070. Epub 2016 Dec 2.

PMID:
27571246
35.

Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.

Bol KF, van den Bosch T, Schreibelt G, Mensink HW, Keunen JE, Kiliç E, Japing WJ, Geul KW, Westdorp H, Boudewijns S, Croockewit SA, van Rossum MM, de Goede AL, Naus NC, van der Graaf WT, Gerritsen WR, de Klein A, Punt CJ, Figdor CG, Cohen VM, Paridaens D, de Vries IJ.

Ophthalmology. 2016 Oct;123(10):2265-7. doi: 10.1016/j.ophtha.2016.06.027. Epub 2016 Jul 29. No abstract available.

PMID:
27476772
36.

Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines.

Bakdash G, Buschow SI, Gorris MA, Halilovic A, Hato SV, Sköld AE, Schreibelt G, Sittig SP, Torensma R, Duiveman-de Boer T, Schröder C, Smits EL, Figdor CG, de Vries IJ.

Cancer Res. 2016 Aug 1;76(15):4332-46. doi: 10.1158/0008-5472.CAN-15-1695. Epub 2016 Jun 20.

37.

Dendritic cell vaccination in melanoma patients: From promising results to future perspectives.

Boudewijns S, Bloemendal M, Gerritsen WR, de Vries IJ, Schreibelt G.

Hum Vaccin Immunother. 2016 Oct 2;12(10):2523-2528. doi: 10.1080/21645515.2016.1197453. Epub 2016 Jun 20.

38.

Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.

Boudewijns S, Westdorp H, Koornstra RH, Aarntzen EH, Schreibelt G, Creemers JH, Punt CJ, Figdor CG, de Vries IJ, Gerritsen WR, Bol KF.

J Immunother. 2016 Jul-Aug;39(6):241-8. doi: 10.1097/CJI.0000000000000127.

39.

T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines.

Vasaturo A, Halilovic A, Bol KF, Verweij DI, Blokx WA, Punt CJ, Groenen PJ, van Krieken JH, Textor J, de Vries IJ, Figdor CG.

Cancer Res. 2016 Jun 15;76(12):3496-506. doi: 10.1158/0008-5472.CAN-15-3211. Epub 2016 Apr 11.

40.

Dendritic Cell-Based Immunotherapy: State of the Art and Beyond.

Bol KF, Schreibelt G, Gerritsen WR, de Vries IJ, Figdor CG.

Clin Cancer Res. 2016 Apr 15;22(8):1897-906. doi: 10.1158/1078-0432.CCR-15-1399. Review.

41.

Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition.

Tel J, Koornstra R, de Haas N, van Deutekom V, Westdorp H, Boudewijns S, van Erp N, Di Blasio S, Gerritsen W, Figdor CG, de Vries IJ, Hato SV.

J Transl Med. 2016 Apr 14;14:88. doi: 10.1186/s12967-016-0844-6.

42.

Opportunities for immunotherapy in microsatellite instable colorectal cancer.

Westdorp H, Fennemann FL, Weren RD, Bisseling TM, Ligtenberg MJ, Figdor CG, Schreibelt G, Hoogerbrugge N, Wimmers F, de Vries IJ.

Cancer Immunol Immunother. 2016 Oct;65(10):1249-59. doi: 10.1007/s00262-016-1832-7. Epub 2016 Apr 8. Review.

43.

A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets.

Sittig SP, Bakdash G, Weiden J, Sköld AE, Tel J, Figdor CG, de Vries IJ, Schreibelt G.

Mediators Inflamm. 2016;2016:3605643. doi: 10.1155/2016/3605643. Epub 2016 Feb 7.

44.

Long-lasting multifunctional CD8+ T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination.

Wimmers F, Aarntzen EH, Duiveman-deBoer T, Figdor CG, Jacobs JF, Tel J, de Vries IJ.

Oncoimmunology. 2015 Aug 12;5(1):e1067745. eCollection 2016.

45.

Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination.

Bol KF, Aarntzen EH, Hout FE, Schreibelt G, Creemers JH, Lesterhuis WJ, Gerritsen WR, Grunhagen DJ, Verhoef C, Punt CJ, Bonenkamp JJ, de Wilt JH, Figdor CG, de Vries IJ.

Oncoimmunology. 2015 Jun 5;5(1):e1057673. eCollection 2016.

46.

Innate Lymphoid Cells in Tumor Immunity.

van Beek JJP, Martens AWJ, Bakdash G, de Vries IJM.

Biomedicines. 2016 Feb 25;4(1). pii: E7. doi: 10.3390/biomedicines4010007. Review.

47.

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.

Bol KF, Aarntzen EH, Pots JM, Olde Nordkamp MA, van de Rakt MW, Scharenborg NM, de Boer AJ, van Oorschot TG, Croockewit SA, Blokx WA, Oyen WJ, Boerman OC, Mus RD, van Rossum MM, van der Graaf CA, Punt CJ, Adema GJ, Figdor CG, de Vries IJ, Schreibelt G.

Cancer Immunol Immunother. 2016 Mar;65(3):327-39. doi: 10.1007/s00262-016-1796-7. Epub 2016 Feb 10.

48.

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.

Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EH, Duiveman-de Boer T, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, Olde Nordkamp MA, van Oorschot TG, Tel J, Winkels G, Petry K, Blokx WA, van Rossum MM, Welzen ME, Mus RD, Croockewit SA, Koornstra RH, Jacobs JF, Kelderman S, Blank CU, Gerritsen WR, Punt CJ, Figdor CG, de Vries IJ.

Clin Cancer Res. 2016 May 1;22(9):2155-66. doi: 10.1158/1078-0432.CCR-15-2205. Epub 2015 Dec 28.

49.

Recurrent candidiasis and early-onset gastric cancer in a patient with a genetically defined partial MYD88 defect.

Vogelaar IP, Ligtenberg MJ, van der Post RS, de Voer RM, Kets CM, Jansen TJ, Jacobs L, Schreibelt G; International Gastric Cancer Genetics Group, de Vries IJ, Netea MG, Hoogerbrugge N.

Fam Cancer. 2016 Apr;15(2):289-96. doi: 10.1007/s10689-015-9859-z.

50.

Primary Human Blood Dendritic Cells for Cancer Immunotherapy-Tailoring the Immune Response by Dendritic Cell Maturation.

Sittig SP, de Vries IJM, Schreibelt G.

Biomedicines. 2015 Dec 2;3(4):282-303. doi: 10.3390/biomedicines3040282. Review.

Supplemental Content

Loading ...
Support Center